P. 474

An Urban Experience
Table 1: Non-Pharmacologic Multimodal Management of Cachexia and Sarcopenia
While there is no single therapy shown to mitigate muscle loss associated with aging and disease, a multimodal approach including nutritional and exercise therapies
can provide meaningful bene ts that improve quantity and quality of life in our aging, diseased patients. The human medical community has made great strides towards better understanding and slowing these clinically important syndromes. As a profession, veterinarians are charged with following this exploration into these critical, devastating syndromes and have taken the  rst steps through creation of muscle condition scoring systems and pilot studies documenting that such syndromes indeed exist in our patient population.
1. National Institute on Aging. Global Health and Aging. Available at: Accessed Feb 28, 2017.
2. Idexx Laboratories, Data on File 2017.
3. Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism 1970; 19: 653–663.
4. Tan BH, Fearon KC. Cachexia: Prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008; 11: 400–407.
5. Ali S., Garcia JM. Sarcopenia, cachexia and aging: Diagnosis, mechanisms and therapeutic options. Geron 2014; 60(4): 294-305.
6. Schaap LA, Pluijm SM, Deeg DJ, et al. Higher in ammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci 2009; 64(11): 1183-1189.
7. Mantovani G, Maccio A, Madeddu C, et al. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med 2003; 81: 664–673.
8. Little JP, Phillips SM. Resistance exercise and nutrition to counteract muscle wasting. Appl Physiol Nutr Metab 2009; 34: 817–828.
9. Freeman LM, Rush JE, Kehayias JJ, et al. Nutritional alterations and the effect of  sh oil supplementation on dogs with heart failure. J Vet Intern Med 1998; 12(6): 440-448.
10. Fritsch DA, Jewell DA. Acceptance and effects of a therapeutic renal food in pet cats with chronic kidney disease. J Rec 2015; 2.
11. Hall JA, Fritsch DA, Yerramilli M, et al. A longitudinal study on the acceptance and effects of a therapeutic renal food in pet dogs with IRIS-Stage 1 chronic kidney disease. JAPAN 2017; In Press.

   472   473   474   475   476